Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 334

1.

Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients.

Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E.

J Am Acad Dermatol. 2011 Sep;65(3):552-8. doi: 10.1016/j.jaad.2010.07.032.

PMID:
21641080
2.

Rituximab in autoimmune bullous diseases: mixed responses and adverse effects.

Schmidt E, Seitz CS, Benoit S, Bröcker EB, Goebeler M.

Br J Dermatol. 2007 Feb;156(2):352-6.

PMID:
17223877
3.

[Efficacy of rituximab in a case of refractory bullous pemphigoid].

Reguiaï Z, Tchen T, Perceau G, Bernard P.

Ann Dermatol Venereol. 2009 May;136(5):431-4. doi: 10.1016/j.annder.2008.10.038. Epub 2009 Feb 26. French.

PMID:
19442800
4.

Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).

Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R.

Dermatology. 2007;214(4):310-8.

PMID:
17460402
5.
6.

Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris.

Behzad M, Möbs C, Kneisel A, Möller M, Hoyer J, Hertl M, Eming R.

Br J Dermatol. 2012 Apr;166(4):844-52. doi: 10.1111/j.1365-2133.2011.10732.x.

PMID:
22092243
7.

Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data.

Gürcan HM, Ahmed AR.

Am J Clin Dermatol. 2009;10(6):383-96. doi: 10.2165/11310740-000000000-00000. Review.

PMID:
19824739
8.

Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody).

Dupuy A, Viguier M, Bédane C, Cordoliani F, Blaise S, Aucouturier F, Bonnetblanc JM, Morel P, Dubertret L, Bachelez H.

Arch Dermatol. 2004 Jan;140(1):91-6.

PMID:
14732665
9.

Sustained clinical response to rituximab in a case of life-threatening overlap subepidermal autoimmune blistering disease.

Li Y, Foshee JB, Sontheimer RD.

J Am Acad Dermatol. 2011 Apr;64(4):773-8. doi: 10.1016/j.jaad.2009.09.045. Epub 2010 May 21.

PMID:
20494477
10.

Low-dose rituximab is effective in pemphigus.

Horváth B, Huizinga J, Pas HH, Mulder AB, Jonkman MF.

Br J Dermatol. 2012 Feb;166(2):405-12. doi: 10.1111/j.1365-2133.2011.10663.x. Epub 2012 Jan 9.

PMID:
21967609
11.

Adjuvant rituximab therapy in pemphigus: a single-center experience of 18 cases.

Baum S, Gilboa S, Greenberger S, Pavlotsky F, Trau H, Barzilai A.

J Dermatolog Treat. 2013 Dec;24(6):427-30. doi: 10.3109/09546634.2013.784391. Epub 2013 May 21.

PMID:
23521340
12.

Rituximab in refractory autoimmune bullous diseases.

Schmidt E, Hunzelmann N, Zillikens D, Bröcker EB, Goebeler M.

Clin Exp Dermatol. 2006 Jul;31(4):503-8. Review.

PMID:
16716150
13.

Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients.

Kim MR, Kim HC, Kim SC.

Dermatology. 2011;223(2):182-8. doi: 10.1159/000332848. Epub 2011 Oct 21.

PMID:
22025028
14.

Rituximab in refractory pemphigus vulgaris.

Sorce M, Aricò M, Bongiorno MR.

Dermatol Ther. 2008 Jul;21 Suppl 1:S6-9. doi: 10.1111/j.1529-8019.2008.00194.x.

PMID:
18727815
15.

Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients.

Matsukura S, Knowles SR, Walsh S, Shear NH.

Arch Dermatol. 2012 Jun;148(6):734-9. doi: 10.1001/archdermatol.2011.3320. Erratum in: Arch Dermatol. 2012 Sep 1;148(9):1012. Dosage error in article text. Arch Dermatol. 2012 Aug;148(8):970. Dosage error in article text.

PMID:
22351790
16.

Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses.

Feldman RJ, Ahmed AR.

Expert Rev Clin Immunol. 2011 Jul;7(4):529-41. doi: 10.1586/eci.11.22. Review.

PMID:
21790294
17.

Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.

Gürcan HM, Ahmed AR.

Ann Pharmacother. 2007 Oct;41(10):1604-10. Epub 2007 Sep 4.

PMID:
17785614
18.

Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up.

Cianchini G, Lupi F, Masini C, Corona R, Puddu P, De Pità O.

J Am Acad Dermatol. 2012 Oct;67(4):617-22. doi: 10.1016/j.jaad.2011.11.007. Epub 2012 Jan 13.

PMID:
22243765
19.
20.

Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases.

Kasperkiewicz M, Eming R, Behzad M, Hunzelmann N, Meurer M, Schulze-Koops H, von Wussow P, Hertl M, Zillikens D, Freivogel K, Dörner T, Schmidt E.

J Dtsch Dermatol Ges. 2012 Oct;10(10):727-32. doi: 10.1111/j.1610-0387.2012.07931.x. Epub 2012 May 11.

PMID:
22577946

Supplemental Content

Support Center